Anika Therapeutics | ANIK - Debt


Anika Therapeutics reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Abbott USD 34.05B 20.19B Mar/2026
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 725.8M 1.82M Jun/2026
Integra LifeSciences USD 2.04B 6.27M Mar/2026
Intrexon USD 0 13.82M Jun/2024
J&J USD 49.04B 5.95B Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
MacroGenics USD 36.51M 500K Mar/2026
Merit Medical Systems USD 821.56M 9K Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Stryker USD 14.19B 32M Jun/2026
Veracyte USD 39.33M 321K Mar/2026
Xencor USD 175.16M 12.58M Mar/2026
Zimmer Biomet Holdings USD 7.48B 8M Jun/2026